ArisGlobal logo
Verified via Expert Interviews

ArisGlobal: Revenue, Valuation & Competitors

ArisGlobal company overview

Ownership
PE-backed
Employees
1,977
Investors
Nordic Capital
Revenue / FTE
$6•k

About

Multi-tenant SaaS drug development technology platform for global life sciences companies to automate pharmacovigilance, regulatory, quality, and medical affairs workflows.
Verified via Expert Interviews

Expert Vetted Data

Public disclosures rarely capture a company's internal dynamics or the true state of its technology. Gain first-hand insight by speaking with former ArisGlobal executives.

Ownership & Key Financials

Revenue

$1••m '••
1

Investors

Nordic Capital
'21

Revenue / FTE

$6•k '••
1

Ownership

PE-backed

FTEs

1
+4% CAGR
1607
2020
1804
2021
2095
2022
2140
2023
1977
2024

Legal Disclaimer

The company profiles displayed here are abridged, indicative previews of the full, proprietary data available within the Dialectica Origin Platform, derived from confidential sources and expert-vetted research. This content is the exclusive Intellectual Property (IP) of Dialectica. Your access does not grant any rights to the data. Systematic copying, scraping, crawling, indexing, or extraction, whether by manual means, automated software, bots, or Large Language Models (LLMs), is strictly prohibited and violates our Terms of Use.

This information is provided 'as is' for promotional purposes only; Dialectica disclaims all liability for its accuracy, completeness, or any reliance placed upon it.